Long-Acting Injectable PrEP: Advances in HIV Prevention

In an era of rapid medical advancement, one of the most groundbreaking innovations bringing new hope to humanity is the Long-Acting PrEP Injection — a preventive treatment that reduces the risk of HIV infection by more than 99%, without the need to take daily pills. In the past, people relied on daily PrEP tablets (Pre-Exposure Prophylaxis) to protect themselves against HIV. However, this Long-Acting PrEP Injection has completely changed the way prevention works. With just a few injections per year, individuals can stay protected for months at a time. This medical breakthrough represents a major step forward for modern healthcare — not only reducing new HIV infections but also providing a crucial tool in the global mission to end AIDS sustainably by 2030, as envisioned by the United Nations (UNAIDS).

List of Contents

1. What is a Long-Acting PrEP Injection?
2. Cabotegravir
3. Lenacapavir
4. Who is suitable for this Long-Acting PrEP Injection?
5. Frequently Asked Questions

What is a Long-Acting PrEP Injection?

The Long-Acting PrEP Injection, also known as Injectable PrEP, is a long-acting antiretroviral innovation that prevents HIV from entering human cells. It provides strong and continuous protection without the need for daily dosing.

Currently, there are two major types of Long-Acting PrEP Injections recognized worldwide:

• Cabotegravir (Apretude®) – lasts for two months per injection
• Lenacapavir (Yeztugo®) – the latest version lasting up to six months per injection

Both are designed to replace the need for daily oral PrEP pills, as the drug is slowly released into the bloodstream, maintaining sufficient levels to prevent HIV infection effectively.

Cabotegravir: The First Long-Acting PrEP Injection That Transformed HIV Prevention

Cabotegravir, an Integrase Inhibitor, became the first FDA-approved Long-Acting PrEP Injection in late 2021 under the brand name Apretude. The treatment begins with two intramuscular injections one month apart, followed by an injection every two months to maintain consistent drug levels in the body. Clinical studies such as HPTN 083 (among men who have sex with men) and HPTN 084 (among women in Africa) demonstrated that Cabotegravir provides 66–89% higher protection than daily oral PrEP.
This success is largely because users no longer need to remember to take pills daily — one of the biggest barriers to effective HIV prevention in the past.

Lenacapavir: The New-Generation Long-Acting PrEP Injection — Only Twice a Year

Lenacapavir for HIV prevention, sold under the brand name Yeztugo, was approved by the U.S. FDA on June 18, 2025, as a Long-Acting PrEP Injection that provides up to six months of protection with just one dose. (Lenacapavir was earlier approved for HIV treatment under the brand name Sunlenca, used as part of a combination regimen.) Lenacapavir belongs to a novel drug class called Capsid Inhibitors, which work differently from older HIV prevention drugs. It blocks the activity of the viral capsid, preventing HIV from replicating and spreading in the body.

Key advantages of Lenacapavir:

• Only two injections per year for long-term protection
• Minimal side effects, mainly mild pain at the injection site
• Ideal for individuals who value convenience and privacy, or cannot attend frequent clinic visits

The World Health Organization (WHO) and UNAIDS have welcomed lenacapavir as an important advance in HIV prevention, reinforcing its role as a cornerstone innovation toward the goal of Ending AIDS by 2030.

Find a PrEP service that fits your needs * Prices and free services vary by provider. Please check the details before booking. View PrEP services → 03

Comparison Between 2-Month and 6-Month Long-Acting PrEP Injections

Category	Cabotegravir (Apretude)	Lenacapavir (Yeztugo)
Drug Class	Integrase Inhibitor	Capsid Inhibitor
Injection Frequency	Every 2 months	Every 6 months
Administration Method	Intramuscular injection	Subcutaneous injection
Initiation Process	Requires an HIV test before each start	Requires HIV testing before initiation as well
Common Side Effects	Pain or swelling at the injection site	Mild pain under the skin
Approval Status	Approved by FDA and WHO	FDA-approved for HIV prevention (Yeztugo, June 18, 2025)
Effectiveness	Highly effective at reducing sexually acquired HIV when used as directed (HPTN 083 and 084)	Highly effective at reducing sexually acquired HIV when used as directed (PURPOSE trials)

Long-Acting PrEP Injection: A New Hope for Ending AIDS

The arrival of Long-Acting PrEP Injections represents a strategic breakthrough in the fight against HIV. These injections can significantly reduce the number of new HIV infections worldwide—particularly among high-risk groups such as:

• LGBTQ+ youth
• People with limited access to healthcare
• People who inject drugs
• Individuals with multiple sexual partners

According to UNAIDS, there are over 1.3 million new HIV infections each year globally, and more than 50% occur among populations who struggle to maintain consistent access to daily oral PrEP. This is why the development of long-acting injectable PrEP is so critical — it helps bridge the prevention gap and ensures broader, more equitable protection for everyone.

Is the Long-Acting PrEP Injection Safe?

Both Cabotegravir and Lenacapavir have undergone large-scale clinical trials involving thousands of volunteers worldwide, showing that they are safe, effective, and well tolerated.

• Common side effects may include:
• Mild pain or tightness at the injection site
• Slight redness or swelling
• Temporary fatigue in some users

Overall, most users report that the injections are more convenient and easier to maintain compared to taking daily pills.

Who Is Suitable for the Long-Acting PrEP Injection?

The Long-Acting PrEP Injection is ideal for individuals at high risk of HIV infection or those who find it difficult to take daily medication consistently, such as:

• People who often forget to take their pills
• Those who prefer not to carry medication with them
• Individuals who experience side effects from oral PrEP
• People who value privacy and discretion in their prevention method

Before starting the injection, a doctor will conduct an HIV test to ensure the person is HIV-negative. Once confirmed, the injection can be administered on schedule, with follow-up visits as recommended by the healthcare provider.

Related Articles

• Lenacapavir PrEP Shot is Now FDA-Approved for HIV Prevention
• Starting PrEP the Right Way: A Complete Safety Guide

HIV Prevention Injection in Thailand

Access to Long-Acting PrEP Injections in Thailand may vary, and availability is not confirmed here — please check current local information. Where injectable PrEP has been offered, it has generally been through pilot programs involving cabotegravir at selected sexual health clinics, in collaboration with the Department of Disease Control (DDC), rather than lenacapavir (Yeztugo), which is not necessarily in service in Thailand yet. Discussions about including Long-Acting PrEP under Universal Health Coverage (UHC) are ongoing; check current local sources for the latest status.

Plan your PrEP care with a provider * Prices and free services vary by provider. Please check the details before booking. Find a clinic → 04

Beyond Medicine: Changing Social Attitudes Toward HIV Prevention

The introduction of the HIV prevention injection is not just a medical advancement — it represents a social transformation. It has encouraged people to speak more openly about sexual health, helping to break down stigma, fear, and shame long associated with HIV. Today, prevention is everyone’s responsibility — regardless of gender, sexuality, or background. The Long-Acting PrEP Injection empowers individuals to take control of their sexual health confidently, with less anxiety and more privacy.

Looking Ahead: The New Era of HIV Prevention

In the coming years, researchers predict the arrival of Long-Acting PrEP Injections that can last up to one full year, or even HIV vaccines, which are currently under clinical trials. As of today, the existing 2-month and 6-month Long-Acting PrEP Injections are one effective option among several in the global effort to end AIDS. They offer real benefits, but also have limitations and cost and access considerations, so the choice is best made through shared decision-making with a healthcare provider.

Frequently Asked Questions About Long-Acting PrEP Injection

1. Do I need an HIV test before every injection?

Yes. Before the first dose and each subsequent injection, doctors will perform an HIV test to confirm that you are still HIV-negative. If a person is already infected, the injection will not work as prevention — instead, they will be switched to a treatment regimen to ensure safety and effectiveness.

2. What if I miss my scheduled injection?

If you miss your appointment by only a few days, there may still be some residual protection. However, you should not delay too long, as the drug level in your body will decrease and protection will weaken. Contact your doctor or clinic as soon as possible to schedule your next injection.

3. Does the Long-Acting PrEP Injection protect against other STIs?

No. The injection prevents HIV only — it does not protect against other sexually transmitted infections such as gonorrhea, syphilis, or herpes. Using condoms alongside PrEP remains the best way to protect yourself from all STIs.

4. Can I use the injection along with birth control?

Yes. There is no evidence that the Long-Acting PrEP Injection interferes with hormonal contraceptives — whether they are oral, injectable, or implants. However, if you have underlying health conditions or are taking other medications, consult your healthcare provider first.

5. What should I do if I want to stop taking the injection?

You can stop under medical supervision. It’s important to note that the drug can remain in your system for an extended period after the last injection, and this long pharmacologic tail varies by product. Stopping safely requires ongoing HIV testing, keeping injections on time until you switch, and a clear plan to move to another PrEP method — follow your product’s specific guidance. During this transition, use alternative protection such as condoms or oral PrEP to avoid a gap in prevention coverage.

6. Is the Long-Acting PrEP Injection available at all clinics in Thailand?

Availability varies and is not confirmed here — please check current local information. Where injectable PrEP has been offered in Thailand, it has generally been through pilot programs at sexual health clinics and specialized medical centers and has involved cabotegravir rather than lenacapavir (Yeztugo). Wider access, including under Universal Health Coverage, may expand in the future; please check current local sources.

Conclusion: Long-Acting PrEP — A New Hope for a World Without AIDS

The Long-Acting PrEP Injection marks a major leap in modern medicine, making HIV prevention more convenient, practical, and sustainable than ever before.
It is both a life-saving innovation and a symbol of health equity, reminding us that:

“Sexual health is not a privilege for some — it’s a right for everyone.”

The Long-Acting PrEP Injection is one effective, convenient option that can help move toward a future with fewer HIV infections — where prevention is simpler, more stigma-free, and more accessible, chosen through shared decision-making and weighed against its cost and access considerations. 🌍💙

References:

• Injectable Long-Acting Cabotegravir–Rilpivirine Therapy
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC9951790
• Is Injectable PrEP Better Than Oral Medication for HIV Prevention?
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC10410461
• Yeztugo Lenacapavir Is the First and Only FDA-Approved Option for HIV Prevention
  • https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection

Verified references

Links and relevance to the article’s main topic were reviewed on 13 August 2026. Each source supports only the scope stated in the original document and does not replace personalised medical, legal, or service advice.

1. WHO: Recommendation for injectable lenacapavir for HIV prevention Accessed 13 August 2026
2. US FDA: Yeztugo prescribing information Accessed 13 August 2026
3. CDC: Clinical Guidance for PrEP Accessed 13 August 2026